Literature DB >> 11369114

A model for the induction of aplastic anemia by subcutaneous administration of benzene in mice.

R Velasco Lezama1, E Barrera Escorcia, A Muñoz Torres, R Tapia Aguilar, C González Ramírez, M García Lorenzana, V Ortiz Monroy, M Betancourt Rule.   

Abstract

Long-term exposure to benzene vapors is associated with hematological diseases such as leukemia, lymphoma and aplastic anemia. CD(1) male mice were randomly assigned to six groups: 1B(10), 1B(15), 1B(20), 2B(10), 2B(15), and 2B(20.) 1B mice were administered 2 ml/kg (1940 mg/kg) subcutaneous injection (in the dorsal region) of benzene 5 days a week, and 2B mice were exposed 3 days a week (Monday, Wednesday and Friday) until a total of 10, 15 and 20 doses were completed. About 48 h after treatment completion, leukocyte, erythrocyte, and bone marrow cells were counted, and spleen histopathology was analyzed. 1B(15) and 1B(20) mice showed lethargy and irritability, 80% body and 42% spleen weight loss (P<0.001), while body and spleen weight loss were less severe in 2B mice (12 and 48%, respectively). After exposure to 20 benzene doses, 1B(20) and 2B(20) mice showed decreased hemoglobin concentrations, and erythrocyte, leukocyte and bone marrow cell counts (37, 34, 80 and 50%, respectively in group 1B(20); P<0.001; and 12, 48, 62 and 62%, respectively in group 2B(20)). Thrombocytopenia occurred only in group 2B. Both benzene-treatment schemes caused aplastic anemia, however, the disease was masked by spleen toxicity in group 1B. Scheme 2 allowed mice survival and caused less non-hematological effects. We establish here a reproducible and inexpensive experimental model to induce aplastic anemia in mice by subcutaneous injection of 2 ml/kg benzene, using two short-term treatment schemes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369114     DOI: 10.1016/s0300-483x(01)00371-7

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  8 in total

Review 1.  Animal models for acquired bone marrow failure syndromes.

Authors:  Jichun Chen
Journal:  Clin Med Res       Date:  2005-05

2.  Genetic and environmental factors influencing human diseases with telomere dysfunction.

Authors:  Hinh Ly
Journal:  Int J Clin Exp Med       Date:  2009-05-31

3.  Investigation into variation of endogenous metabolites in bone marrow cells and plasma in C3H/He mice exposed to benzene.

Authors:  Rongli Sun; Juan Zhang; Lihong Yin; Yuepu Pu
Journal:  Int J Mol Sci       Date:  2014-03-20       Impact factor: 5.923

4.  Histone Deacetylase Inhibitors Trichostatin A and MCP30 Relieve Benzene-Induced Hematotoxicity via Restoring Topoisomerase IIα.

Authors:  Jingjing Chen; Zhouyi Zheng; Yi Chen; Jiaqi Li; Shanhu Qian; Yifen Shi; Lan Sun; Yixiang Han; Shenghui Zhang; Kang Yu
Journal:  PLoS One       Date:  2016-04-08       Impact factor: 3.240

5.  Benzene induces haematotoxicity by promoting deacetylation and autophagy.

Authors:  Shanhu Qian; Yixiang Han; Yifen Shi; Wanling Xu; Yiyi Zhu; Songfu Jiang; Yi Chen; Zhijie Yu; Si Zhang; Yiping Yang; Kang Yu; Shenghui Zhang
Journal:  J Cell Mol Med       Date:  2018-11-08       Impact factor: 5.310

6.  Ameliorative Effects of Bovine Lactoferrin on Benzene-Induced Hematotoxicity in Albino Rats.

Authors:  Mohamed F Abou Elazab; Asmaa E A Elbaiomy; Mohamed S Ahmed; Khalaf F Alsharif; Naief Dahran; Ehab Kotb Elmahallawy; Abdallah A Mokhbatly
Journal:  Front Vet Sci       Date:  2022-06-22

Review 7.  Mesenchymal Stem Cell Benefits Observed in Bone Marrow Failure and Acquired Aplastic Anemia.

Authors:  Vivian Fonseca Gonzaga; Cristiane Valverde Wenceslau; Gustavo Sabino Lisboa; Eduardo Osório Frare; Irina Kerkis
Journal:  Stem Cells Int       Date:  2017-12-03       Impact factor: 5.443

8.  IL-11 promotes the treatment efficacy of hematopoietic stem cell transplant therapy in aplastic anemia model mice through a NF-κB/microRNA-204/thrombopoietin regulatory axis.

Authors:  Yan Wang; Zhi-Yun Niu; Yu-Jie Guo; Li-Hua Wang; Feng-Ru Lin; Jing-Yu Zhang
Journal:  Exp Mol Med       Date:  2017-12-08       Impact factor: 8.718

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.